HeartFlow Announces New Commercial Coverage with UnitedHealthcare,
Largest Health Insurer in U.S.
HeartFlow Analysis Now Covered for more than 75% of Americans
REDWOOD CITY, Calif. - June 27, 2018 -
today announced that
UnitedHealthcare now covers the HeartFlow
FFRct Analysis, extending access to their 45
million beneficiaries. With this new coverage, more than 235 million people in the United States
now have access to the HeartFlow Analysis -- significantly advancing HeartFlow’s mission of
transforming cardiovascular care. The HeartFlow Analysis is a non-invasive technology that
uses a coronary computed tomography angiogram (CTA) to create a personalized 3D model of
the heart and simulate blood flow in order to help clinicians diagnose and treat people with
suspected coronary artery disease (CAD).
In a new coverage decision, UnitedHealthcare also chose to adopt the medical policy for
coronary CTA from eviCore, an evidence-based specialty benefits management company. The
policy allows for the use of a coronary CTA as a first-line test for symptomatic individuals,
removing the need for a standard stress test prior to conducting a coronary CTA. In addition, the
HeartFlow Analysis is now approved to further assess coronary disease seen on a coronary
CTA that is of uncertain physiological significance.
“This decision by UnitedHealthcare underscores the significant value that the HeartFlow
Analysis brings to payers, physicians and patients, from both a clinical and economic
standpoint,” said John H. Stevens, M.D., president and chief executive officer of HeartFlow. “Not
only is the HeartFlow Analysis now accessible to tens of millions of additional people, but this
advancement also positions HeartFlow as an integral part of the standard approach to heart
disease diagnosis and treatment.”
CAD affects 16.8 million Americans
and develops when the coronary arteries narrow, reducing
blood flow to the heart and potentially causing chest pain (angina), heart attack (myocardial
infarction) and death.
About the HeartFlow Analysis
Clinicians diagnosing someone with suspected CAD want to know as definitively as possible if
the individual has a significant blockage in their coronary arteries. They also want to know the
impact of that blockage on blood flow so they can best determine which treatment pathway is
appropriate (e.g., medical management, stenting or coronary artery bypass grafting).
Data from a patient’s non-invasive coronary CTA are securely uploaded from the hospital’s
system to the cloud. HeartFlow leverages deep learning to create a personalized, digital 3D
model of the patient’s coronary arteries. The HeartFlow Analysis then uses powerful computer
algorithms to solve millions of complex equations to simulate blood flow and assess the impact
of blockages on coronary blood flow. The HeartFlow Analysis is provided via a secure online
interface to offer actionable information to enable clinicians to determine the optimal course of
treatment. To date, clinicians around the world have used the HeartFlow Analysis for more than
20,000 patients to aid in the diagnosis of heart disease.
This technology has been demonstrated to reduce unnecessary and invasive diagnostic
coronary angiography procedures, which can be associated with bleeding, stroke, major blood
vessel damage and other serious complications. It also significantly reduces healthcare costs
About HeartFlow, Inc.
HeartFlow, Inc. is a medical technology company transforming the way heart disease is
diagnosed and treated. Our non-invasive HeartFlow Analysis leverages deep learning to create
a personalized 3D model of the heart. By using this model, clinicians can better evaluate the
impact a blockage has on blood flow and determine the best treatment for patients. Our
technology is reflective of our Silicon Valley roots and incorporates decades of scientific
evidence with the latest advances in artificial intelligence. The HeartFlow Analysis is
commercially available in the United States, Canada, Europe and Japan. For more information,
# # #
Douglas PS, DeBruyne B, Pontone G., Patel MR, et al. One-year outcomes of FFRCT-guided care in patients with
suspected coronary disease: The PLATFORM Study.
J Am Coll Cardiol